As coronavirus cases continue to rise, the UK plans to move fast in the approval process and clearance to Pfizer and BioNTech SE could come by next week

The vaccine supplies for the global market will be produced by RDIF's international partners in India, Brazil, China, South Korea and other countries. The safety of vaccines based on human adenoviruses has been confirmed in more than 75 international publications and in more than 250 clinical trials.

The Russian Gamaleya research institute, the creator of Sputnik V vaccine for COVID-19, has suggested to UK pharmaceutical company AstraZeneca to try to boost the efficacy of its COVID-19 vaccine, combining it with a shot of its own vaccine.

Two-wheeler exports to witness stable growth in second half of FY21-22; Corporate debt reduces by Rs 68,000 cr in H1FY21; RIL, IOC, BPCL ease burden; India bans 43 Chinese mobile apps, under Section 69A of the Information Technology Act. Watch this and more on News Blast.Also Read: Relief for depositors! Lakshmi Vilas Bank's withdrawal restrictions lifted

The world of vaccine and drug development is being reset. Here's how Indian pharma must reinvent to lead the new era of drug discovery and research

A blow-by-blow account of how Indian vaccines are being readied

Ali Express, AliPay, CamCard among 43 Chinese apps banned India on Tuesday banned 43 Chinese mobile apps, under Section 69A of the Information Technology Act. The government said the apps engaged in activities \"prejudicial to India's sovereignty, integrity, defence, security, and public order.\" The list of banned apps include AliExpress, AliSuppliers, Lalamove India, Mango TV amongst others.Russia's Sputnik V shows 90% efficacy against COVID-19; to be priced under $20Russia has claimed...

Kremlin spokesperson has said that Russia has not yet begun widespread vaccination and that Putin can't use an uncertified vaccine

Russia's Sputnik V coronavirus vaccine has shown 95% efficacy, according to a second interim analysis of its human clinical trial data

The twin crises of the pandemic and an uneven, uncertain global recovery dominated the first day of a two-day summit under the chairmanship of Saudi Arabia, which hands off the rotating presidency of the G20 to Italy next month

Emboldened, firms indulge in a game of one-upmanship based on alarmingly low number of trials. Sputnik had been tried on only 20 patients before Gamaleya made the claim; Pfizer 120 and Moderna 95

Late-stage trials of the Oxford vaccine are still awaited but hopes are high that it'll also join frontrunners' league with Pfizer, Moderna and Russia's Sputnik V

Pfizer and BioNTech informed that primary efficacy analysis of their coronavirus vaccine candidate showed that it was 95 per cent effective beginning 28 days after the first dose

Pfizer says Phase 3 study of their COVID-19 vaccine candidate met \"all primary efficacy endpoints\".  During its early analysis, vaccine had shown 90 per cent efficacy but final analysis involving 170 confirmed cases of COVID-19 showed 95 per cent efficacy

Union Health Secretary Rajesh Bhushan spoke about the upsurge in number of COVID-19 cases in Delhi and the action plan made by the health ministry in cooperation with the Delhi government, Indian Council of Medical Research, NITI Aayog and AIIMS

These early efficacy figures don't tell the whole story. The data results are based on a relatively smaller group of participants who received these vaccine shots. The actual efficacy could be known only after the final results are out as Phase 3 clinical trials end

The approval to conduct Phase 2 and Phase 3 trials was granted to Dr Reddy's laboratory by the Drug Controller General of India (DCGI)

Russian news agency TASS says Putin also proposed an increase in the pace of the creation of a vaccine research centre for BRICS countries Brazil, Russia, India, China and South Africa

College principal R B Kamal said the effect of the vaccine on the volunteers will be studied for seven months after the same is administered once, twice or thrice within an interval of 21 day

The GAVI alliance said on Friday that the funds for an advance market commitment (AMC) will allow the COVAX facility to buy an initial one billion vaccine doses for 92 eligible countries